Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1465003 | 0.93 | KMT2A (0.50) | KDM1AKMT2AMEN1ALDH1A1OPRD1 | |
| SCHEMBL7467608 | 0.87 | AKR1C1 (0.59) | KMT2AMEN1ALDH1A1OPRD1OPRM1 | |
| SCHEMBL521247 | 0.87 | AKR1C1 (0.54) | KDM1AKMT2AMEN1ALDH1A1OPRD1 | |
| SCHEMBL8587542 | 0.85 | AKR1C1 (0.57) | KMT2AMEN1ALDH1A1OPRD1AKR1C1 | |
| SCHEMBL1626965 | 0.83 | ICMT (0.48) | KMT2AMEN1ALDH1A1OPRD1OPRM1 | |
| SCHEMBL4878231 | 0.83 | HCAR2 (0.46) | KDM1AKMT2AMEN1ALDH1A1OPRD1 | |
| SCHEMBL21874196 | 0.82 | KMT2A (0.57) | KMT2AMEN1ALDH1A1OPRM1OPRL1 | |
| SCHEMBL21873952 | 0.79 | OPRM1 (0.57) | KDM1AKMT2AMEN1ALDH1A1OPRD1 | |
| SCHEMBL3507379 | 0.79 | LMNA (0.54) | KDM1AKMT2AMEN1ALDH1A1OPRD1 | |
| SCHEMBL27736564 | 0.79 | ADAM17 (0.56) | KDM1AKMT2AMEN1ALDH1A1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | EP300, CREBBP, CREB1 | KDM1A 216/4885KMT2A 124/4885MEN1 3511/4885 |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | EP300, CREBBP, CREB1 | KDM1A 216/4885KMT2A 124/4885MEN1 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.